Results 201 to 210 of about 93,898 (384)
M24 3-year real world outcomes with benralizumab for severe eosinophilic asthma [PDF]
H. P. Palmer +5 more
openalex +1 more source
ABSTRACT Background Chronic rhinosinusitis with nasal polyps (CRSwNP) impacts patients' concentration, ability to work, and overall quality of life. Current treatment options include topical and oral medications, and surgery. Recent evidence supports the efficacy of biologics in improving symptoms and quality of life.
Baharudin Abdullah +19 more
wiley +1 more source
BLOOD EOSINOPHIL COUNT AND FRACTIONAL EXHALED NITRIC OXIDE AS A COMBINED PREDICTOR OF TREATMENT RESPONSE TO BENRALIZUMAB FOR PATIENTS WITH SEVERE, EOSINOPHILIC ASTHMA [PDF]
Rohit Katial +4 more
openalex +1 more source
ABSTRACT Purpose The rising prevalence of obesity introduces challenges in surgical contexts, including endoscopic sinus surgery (ESS) for chronic rhinosinusitis with nasal polyps (CRSwNP). However, the impact of obesity on ESS outcomes remains underexplored. This study aims to evaluate the association between obesity and surgical complexity, operative
Hen Chaushu +6 more
wiley +1 more source
Sputum immunoglobulin E levels correlate with eosinophilic airway regardless of atopy
Immunoglobulin E (IgE) is a key molecule that induces mast cell activation in allergic inflammation and contributes to type 2/eosinophilic inflammation in asthmatic airways.
Hyo-In Rhyou +4 more
doaj +1 more source
Estimated Asthma Exacerbation Reduction from Omalizumab in an Severe Eosinophilic Asthma Population [PDF]
Thomas B. Casale +7 more
openalex +1 more source
ABSTRACT Background Cell senescence (CS) and lipid metabolism (LM) disorders have been reported in chronic rhinosinusitis with nasal polyps (CRSwNP). However, the mechanism is still unclear. Methods Data were obtained from public databases; differential expression analysis and machine learning were performed to identify biomarkers and to understand the
Hui‐Yi Deng +3 more
wiley +1 more source
ABSTRACT Objective Chronic rhinosinusitis with nasal polyps (CRSwNP) is a persistent inflammatory condition often associated with other type‐2 diseases. Dupilumab, a monoclonal antibody targeting IL‐4Rα, has revolutionized the treatment of severe CRSwNP.
Pietro Orlando +17 more
wiley +1 more source
EE135 Cost-Utility Analysis of Benralizumab in Severe Eosinophilic Asthma in Colombia [PDF]
J Ordoñez, Ariana Ordoñez
openalex +1 more source

